Spero Therapeutics (SPRO) EBIT (2016 - 2026)

Spero Therapeutics (SPRO) has reported EBIT for 11 consecutive years, with -$9.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBIT fell 306.14% year-over-year to -$9.9 million; the trailing twelve-month figure through Jun 2026 stood at $6.0 million (up 110.48% YoY), and the FY2025 full-year result was $6.3 million, up 108.61% from the prior year.
• EBIT declined to -$9.9 million in Q2 2026 per SPRO's latest filing, from -$7.5 million in the prior quarter.
• Across five years, EBIT topped out at $50.5 million in Q4 2023 and bottomed at -$30.2 million in Q1 2022.
• Historically, EBIT has averaged -$5.8 million across 5 years, with a median of -$12.4 million in 2022.
• The sharpest annual moves came in 2024 and 2025: EBIT slumped 861.38% in 2024, then soared 244.56% in 2025.
• Over 5 years, EBIT stood at $25.9 million in 2022, then soared by 94.92% to $50.5 million in 2023, then slumped by 142.99% to -$21.7 million in 2024, then jumped by 244.56% to $31.4 million in 2025, then plunged by 131.61% to -$9.9 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$9.9 million, -$7.5 million, and $31.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.